Medication info
Anatel Plus Tablet 80/12.5 mg

Anatel Plus Tablet 80/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Aju Pharmaceuticals Co., Ltd.
Appearance
White or almost white, biconvex, round tablet
Packaging
30 tablets (10 tablets/blister × 3)
Approval status
Active

MFDS item code 201804854 · Approved 2018.11.30 · Insurance code 654005210

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
Adults For patients whose blood pressure is not adequately controlled with telmisartan alone, take once daily with a beverage, with or without food. Before switching to this fixed-dose combination, it is recommended that the dose of each component be individually adjusted. When clinically appropriate, a direct switch from monotherapy to this medicine may also be considered. - The telmisartan/hydrochlorothiazide combination 40/12.5mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 40mg. - The telmisartan/hydrochlorothiazide combination 80/12.5mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg. - The telmisartan/hydrochlorothiazide combination 80/25mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg and hydrochlorothiazide 12.5mg taken as separate products or as a combination product. Sodium or volume depletion should be corrected before starting this medicine. Patients with renal impairment No dosage adjustment is necessary in patients with mild to moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance<30mL/min). Periodic monitoring of renal function is recommended. Patients with hepatic impairment This medicine should be administered with caution to patients with mild to moderate hepatic impairment. The dose of this medicine should not exceed 40/12.5mg once daily. This medicine should not be administered to patients with severe hepatic impairment (see Precautions for Use, section 2). Thiazide diuretics should be administered with caution to patients with impaired hepatic function. Elderly patients No dosage adjustment is necessary.
Child dose
Children under 18 years of age: The safety and efficacy of this medicine have not been established.

Ingredients

Manufacturer
Aju Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

This medication is used for the treatment of essential hypertension and is effectively added to patients whose blood pressure is not sufficiently controlled by telmisartan alone.

How to take

Adult dose

Adults For patients whose blood pressure is not adequately controlled with telmisartan alone, take once daily with a beverage, with or without food. Before switching to this fixed-dose combination, it is recommended that the dose of each component be individually adjusted. When clinically appropriate, a direct switch from monotherapy to this medicine may also be considered. - The telmisartan/hydrochlorothiazide combination 40/12.5mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 40mg. - The telmisartan/hydrochlorothiazide combination 80/12.5mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg. - The telmisartan/hydrochlorothiazide combination 80/25mg may be administered to patients whose blood pressure is not adequately controlled with telmisartan 80mg and hydrochlorothiazide 12.5mg taken as separate products or as a combination product. Sodium or volume depletion should be corrected before starting this medicine. Patients with renal impairment No dosage adjustment is necessary in patients with mild to moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance<30mL/min). Periodic monitoring of renal function is recommended. Patients with hepatic impairment This medicine should be administered with caution to patients with mild to moderate hepatic impairment. The dose of this medicine should not exceed 40/12.5mg once daily. This medicine should not be administered to patients with severe hepatic impairment (see Precautions for Use, section 2). Thiazide diuretics should be administered with caution to patients with impaired hepatic function. Elderly patients No dosage adjustment is necessary.

Child dose

Children under 18 years of age: The safety and efficacy of this medicine have not been established.

Precautions

This medication should not be used during pregnancy, especially in the second and third trimesters, as it can cause serious harm to the fetus. Patients with allergies to this medication's components, pregnant women, breastfeeding women, and those with severe liver or kidney disease should not take this medication. Elderly patients or those with high potassium levels or poor liver function, as well as patients with heart valve disease or cardiomyopathy, should use this medication with caution. The hydrochlorothiazide component may increase the risk of skin cancer by making the skin sensitive to sunlight, so UV protection and skin examinations are necessary during use. Various side effects such as dizziness, hypotension, electrolyte imbalance, liver dysfunction, rash, etc., may occur while taking this medication. Any unusual symptoms should be reported to a doctor immediately. It is particularly important for patients with poor kidney function to have regular blood tests to monitor potassium, creatinine, and other levels. Interactions with other antihypertensive agents, diuretics, lithium, non-steroidal anti-inflammatory drugs, etc., may occur, so inform the doctor of any other medications being taken. Dizziness or drowsiness may occur during driving or operating machinery, so caution is advised. Women planning to become pregnant are recommended to use safer alternative therapies rather than this medication. The safety and efficacy of this medication have not been established in children.

Side effects

  • Hypotension
  • neonatal skull formation deficiency
  • anuria
  • renal failure
  • oligohydramnios
  • limb spasm
  • craniofacial malformation
  • pulmonary hypoplasia
  • prematurity
  • intrauterine growth retardation
Show 112 more
  • patent ductus arteriosus
  • non-melanoma skin cancer
  • bronchitis
  • pharyngitis
  • sinusitis
  • hypokalemia
  • hyperuricemia
  • hyponatremia
  • anxiety
  • depression
  • insomnia
  • sleep disorder
  • dizziness
  • fainting
  • paresthesia
  • visual impairment
  • blurred vision
  • vertigo
  • tachycardia
  • arrhythmia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • respiratory pain
  • pneumonia
  • pulmonary edema
  • diarrhea
  • dry mouth
  • abdominal distension
  • abdominal pain
  • constipation
  • dyspepsia
  • vomiting
  • gastritis
  • abnormal liver function
  • liver disorder
  • vascular edema
  • erythema
  • pruritus
  • rash
  • hyperhidrosis
  • urticaria
  • back pain
  • muscle spasm
  • myalgia
  • arthralgia
  • limb pain
  • systemic lupus erythematosus
  • erectile dysfunction
  • chest pain
  • influenza-like illness
  • pain
  • increased blood uric acid
  • increased blood creatinine
  • increased blood creatine phosphokinase
  • increased liver enzymes
  • upper respiratory infection
  • urinary tract infection
  • cystitis
  • sepsis
  • anemia
  • eosinophilia
  • thrombocytopenia
  • anaphylactic reaction
  • hyperkalemia
  • hypoglycemia
  • drowsiness
  • cough
  • interstitial lung disease
  • eczema
  • drug rash
  • toxic skin rash
  • bone pain
  • renal dysfunction
  • myasthenia
  • decreased hemoglobin
  • sialadenitis
  • non-melanoma skin cancer
  • thrombocytopenic purpura
  • hemolytic anemia
  • bone marrow failure
  • leukopenia
  • agranulocytosis
  • hypersensitivity
  • jaundice
  • cholestasis
  • photosensitivity reaction
  • toxic epidermal necrolysis
  • lupus-like syndrome
  • systemic lupus erythematosus
  • acute renal failure
  • diabetes
  • myasthenia
  • fever
  • nausea
  • gastrointestinal bleeding
  • esophagitis
  • headache
  • tremor
  • facial flushing
  • lethargy
  • fatigue
  • proteinuria
  • itching
  • myalgia
  • lightheadedness
  • tremors of the lips and hands
  • sensory hyperesthesia
  • visual impairment
  • hypoglycemia
  • intestinal vascular edema
  • nausea

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering. A storage temperature between 1 degree Celsius and 30 degrees Celsius is recommended.

Appearance and packaging

Appearance

White or almost white, biconvex, round tablet

Package unit

30 tablets (10 tablets/blister × 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.